Physician profile
Mihaela Ringheanu
NPI 1629059449
$1,269.13
in general payments reported to CMS, 2019-2025
15 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.95 · 2020: $83.34 · 2021: $189 · 2022: $18.83 · 2023: $290 · 2024: $276 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $438.10 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.15 | 2025 | Dupixent |
| Abbvie INC. | $114.10 | 2019-2025 | |
| Perspectum Diagnostics LTD | $111.81 | 2023 | Livermultiscan |
| Takeda Pharmaceuticals U.S.A., INC. | $89.12 | 2021-2025 | Gattex, Eohilia |
| Pfizer INC. | $88.42 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $88.39 | 2023 | Linzess |
| Romark Laboratories, Lc | $48.04 | 2020 | |
| Nestle Healthcare Nutrition INC. | $42.91 | 2021-2022 | |
| Ardelyx, INC. | $24.12 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $21.03 | 2024 | |
| Janssen Biotech, INC. | $20.36 | 2025 | Tremfya |
| Shire North American Group INC | $19.90 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $18.80 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.88 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihaela Ringheanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.